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Abstract 
In colorectal cancer patients, iron therapy, and especially intravenous iron therapy, is increasingly 
used to treat anemia and reduce the use of blood transfusions. However, iron has also been shown to 
be an essential nutrient for rapidly proliferating tissues and cells. In this respect, anemia of 
inflammation, characterized by limited duodenal iron uptake and sequestration of iron into the 
reticuloendothelial system, might be regarded as a potentially effective defense strategy of the human 
body against tumor growth. We therefore hypothesize that iron therapy, by supporting colorectal tumor 
growth and increasing the metastatic potential, may worsen tumor prognosis in colorectal cancer 
patients. This hypothesis is particularly supported  for colorectal cancer by laboratory, epidemiological 
and animal studies, demonstrating the role of iron in all aspects of tumor development growth. 
Compared to non-malignant colon cells, tumor cells differ in the levels and activity of many iron import 
and export proteins, resulting in an increase in intracellular iron level and enhanced proliferation. In 
addition, it is demonstrated that iron is able to amplify Wnt signaling in tumors with Apc mutation, a 
critical mutation in the development of colorectal cancer. If our hypothesis is to be confirmed, current 
practice of iron administration, as treatment for anemia and as replacement of blood transfusions, can 
be hazardous and should be completely reconsidered. 
 
 
 
 
 
 
 
 
 
  
Introduction 
Colorectal cancer is the third most commonly diagnosed cancer in men and the second in women 
worldwide, accounting for more than 1.4 million new cases and 694 000 associated deaths 
worldwide.
1
 Anemia (hemoglobin <12.0 g/dL) is the most frequent hematological manifestation in 
patients with cancer, occurring in >40% of the cases. In colorectal cancer, anemia is even reported in 
around 60% of the cases.
2
 This anemia is most often associated with iron deficiency,
3
 but more 
importantly also with impaired disease-free and overall survival in cancer patients.
4,5
 
As both blood transfusions and erythropoiesis-stimulating agents (ESAs) are, similar to anemia, 
independently associated with an increased risk of colorectal cancer recurrence and increased 
mortality,
6-9
 the use of iron to reverse anemia has gained more attention. In this regard, while oral iron 
does correct anemia, it also causes constipation, and is largely ineffective in patients with anemia of 
inflammation, characterized by reduced duodenal iron uptake and iron mobilization from the reticulo-
endothelial system. In comparison with oral iron, intravenous iron does not have these disadvantages 
and is therefore more and more preferred.
10
 In colorectal cancer patients, several cohort studies have 
shown that intravenous iron therapy indeed optimizes preoperative hemoglobin level. A net reduction 
of blood transfusions by intravenous iron, however, is not conclusively shown as of yet. 
11-14
 
In contrast to the short-term effect of iron therapy to increase the hemoglobin level, strikingly, possible 
long-term effects in colorectal cancer patients, such as survival, are so far hardly studied. These long-
term effects are of special interest since anemia of inflammation is believed to be a potentially defense 
strategy of the human body to limit the growth of tumor cells.
15
 In this respect, the results of laboratory, 
epidemiological and animal studies indeed have shown iron’s role in all aspects of cancer 
development and cancer growth.
11,16-21
 Finally, corroborating evidence implicates that especially 
gastrointestinal cancer cells, likely by their original iron-absorbing nature, have an altered iron 
homeostasis.
22
 
The hypothesis  
We hypothesize that iron therapy may worsen colorectal tumor prognosis by supporting colorectal 
tumor growth and increasing the metastatic potential. Although no direct evidence is available to date, 
accumulative data from experimental studies are in favor of this hypothesis. In this respect, 
importantly, iron therapy is increasingly used with the aim of optimizing hemoglobin level and reducing 
  
the need for blood transfusions. Therefore, this hypothesis is in striking contrast with current practice 
in patient blood management. We evaluated the current evidence supporting this hypothesis in the 
following part.  
Evaluation of the hypothesis   
Iron is an essential nutrient participating in numerous biological and cellular processes such as 
hemoglobin-mediated oxygen transport, DNA synthesis and cell proliferation and growth. As mammals 
do not possess any regulated mechanisms for iron excretion from the body, iron metabolism is 
maintained by the tight control of dietary iron absorption in the duodenum. Intracellular iron transport is 
mainly controlled by three iron transport proteins: 1. divalent metal transporter 1 (DMT1), facilitating 
the transport of dietary iron across the apical membrane of enterocytes 2. ferroportin, facilitating the 
export across the basolateral membrane into the bloodstream, and 3. transferrin receptor 1 (TfR1), 
facilitating the import across the basolateral membrane into the cell. Systemically, iron homeostasis is 
regulated by hepcidin, which is produced by hepatocytes and inhibits the release of iron from 
enterocytes and macrophages into the circulation by inducing the internalization and subsequent 
degradation of ferroportin.
23,24
 The level of hepcidin is controlled by many factors including iron stores, 
hypoxia, anemia and erythropoiesis.
25,26
 Whereas iron deficiency, enhanced red blood cell production, 
and hypoxia decrease hepcidin expression to accelerate iron absorption, iron overload and 
inflammatory stimuli like IL-6 induce increased hepcidin expression. The latter is the cause of a 
hepcidin-mediated decrease in iron uptake and utilization, so called anemia of chronic disease or 
anemia of inflammation. 
Abovementioned background information on the normal regulation of iron metabolism is essential to 
put the modifications in intracellular iron regulation in colorectal cancer cells in perspective. In distinct 
favor of our hypothesis, many transport proteins that were originally studied for their roles in normal 
iron metabolism have now been shown to contribute to malignant tumor growth. Compared to non-
malignant colon cells, iron import proteins, such as DMT1 and TfR1, are upregulated, while ferroportin, 
the only known iron export protein, is downregulated in colon tumor cells, subverting the normal 
homeostatic control into a chronic iron acquisition state enabling enhanced proliferation.
27-29
 More in 
detail, the presence of the key intestinal tumor suppressor Apc seems to play a pivotal role. The Apc 
gene is the most commonly mutated tumor suppressor gene in sporadic colorectal cancer,
30
 and it is 
shown that especially Apc-deficient (i.e. mutant Apc) cells appear critically dependent iron for efficient 
  
tumor growth. In Apc-deficient cells, raising the levels of iron induces the expression of TfR1 and 
DMT1, resulting in increased iron content in the cells and increased proliferation, while removal of iron 
drives apoptosis of Apc-deficient cells. This is the exact opposite to what is observed in colorectal 
cancer cells with wildtype Apc.
17,31
 In addition, it is demonstrated that, in mouse models, the growth 
rate of tumor xenografts is increased by high levels of dietary iron.
32,33
 
Finally, in studying the proliferative effect of iron in colorectal tumors, a clear link between iron and 
Wnt signaling was found
30,34,35
. Wnt signaling plays a critical role in regulating homeostasis and self-
renewal of tissues, and in the intestinal epithelium it promotes proliferation and differentiation of stem 
cells in the intestinal crypts. Aberrant Wnt signaling is closely related to a mutation in Apc, and is an 
important hallmark for colorectal cancer development. Importantly, and supporting our hypothesis, it is 
demonstrated that iron, in the background of an Apc mutation, is able to amplify Wnt signaling, and 
with it induction of cell growth.
36
 Therefore, in the presence of an Apc mutation, iron will affect Wnt 
signaling and with it an increase in the tumorigenic and metastatic potential.
37
  
Consequences of the hypothesis and discussion  
Substantial evidence suggests that iron promotes colorectal tumor growth and potentially increases 
the metastatic potential of colorectal tumor cells. Therefore, the legitimate question arises as to 
whether the use of iron therapy, either orally or intravenously, is a safe and optimal treatment strategy 
in anemic colorectal cancer patients.  
We hypothesize that iron in general (i.e. both oral and intravenous) may worsen colorectal tumor 
prognosis, but the different routes of administration should be considered. In colorectal cancer 
patients, oral iron often is poorly absorbed. As a consequence, only a fraction of the dietary (i.e. orally 
administered) iron will reach the sites of erythropoiesis and a significant part will reach the site of the 
primary tumor. At the site of the primary tumor, the oral iron will be able to affect Wnt signaling and 
contribute to enhanced tumor growth and increased metastatic potential. However, and in contrast 
with intravenous iron, the effect of oral iron will be limited to the primary tumor. In this respect, 
intravenous iron might have more influence if metastases are present. 
In addition to the different routes of administration, we hypothesize that the assessment of type of iron 
deficiency anemia might be important in studying the long-term effect of iron therapy. Chronic blood 
loss, as can be envisioned by bleeding from gastrointestinal tumors, in this respect causes absolute 
  
iron deficiency (AID), characterized by depleted iron stores. Functional iron deficiency (FID), in 
contrast, is caused by impaired iron homeostasis and is, due to increased hepcidin production, 
characterized by reduced iron uptake from the duodenum and iron mobilization from the reticulo-
endothelial system. FID resulting in anemia is also known as anemia of inflammation or anemia of 
chronic disease. Despite definite evidence, FID could be regarded as a potentially effective defense 
strategy to inhibit growth of pathogens and tumor cells.
15
 As, in the event of FID, a large fraction of oral 
iron will, due to poor absorption in the duodenum, reach the site of the primary tumor, we hypothesize 
that iron supplementation will be more hazardous in patients with FID, as compared to patients with 
AID.  
In assessing the effect of iron therapy on tumor growth and tumor prognosis, the dose-response 
relationship will be particularly important. A single dose of intravenous iron normally contains 1000 mg, 
which is, as compared to a daily iron uptake of 1-2 mg, an extremely high amount of extra iron. Total 
body iron is 3-4 g, and this quantity is tightly regulated. However, the body has no mechanism to 
excrete excess iron and only less than 0.1% of total iron is lost on average daily, mostly through urine, 
sweat and feces. Therefore, and despite the relatively large amount of 3-4 g of total body iron, we 
hypothesize that a single dose of intravenous iron or continuous supplementation of oral iron (i.e. 
normally 400-500 mg daily) could already affect tumor growth and therefore be harmful, especially in 
iron-dependent tumors.  
Testing our hypothesis will be challenging. In a retrospective cohort study significant differences 
between an iron-treatment and non-iron treatment group (e.g. baseline hemoglobin levels and use of 
blood transfusions) could, despite possible correction by multivariable regressions analyses, 
potentially indicate selection bias and have significant impact on the outcome. Therefore, to show the 
validity of our hypothesis, the clinical long-term effect of iron therapy should be studied in a 
prospective trial. In such a trial, anemic patients should be randomized into an iron-treatment and a 
non-treatment group. In addition, clinical outcome should be correlated with both tumor (e.g. 
expression levels of iron transporters, Apc status, tumor stage and molecular subtype
38
) and patient 
characteristics. Only such a set up will allow identification of iron-dependent tumor growth and 
potential high-risk patients. Apart from studying the clinical long-term consequences of iron therapy, 
assessing the optimal management of anemia in colorectal cancer patients is more challenging. For 
this purpose, the detrimental long-term effects of iron treatment must be compared with those of not 
  
only anemia, but also alternatives to treat anemia like ESAs and more important blood transfusions. 
The problem here is that a head-to-head comparison of blood transfusion and iron therapy seems 
almost impossible. The indications for both therapies are namely clearly different. Iron therapy is 
indicated in patients with a mild to moderate anemia, while blood transfusion are only administered in 
case of severe anemia. As a useful alternative for clinically assessing the optimal management of 
anemia, animal experiments could be considered. In an ortho- or heterotopic rodent model, the effect 
on tumor growth of both anemia, blood transfusion and iron therapy (both oral and intravenous) could 
be accurately assessed and compared.  
In conducting a prospective trial randomizing anemic patients in an iron-treatment and a non-treatment 
group, ethical issues should be considered. Anemia itself is considered as a major risk factor for 
impaired disease-free and overall survival in cancer patients,
4,5
 and therefore the inclusion of a non-
treatment (i.e. anemic) group could be considered unethical. To challenge this ethical issue, the 
proposed and abovementioned animal experiments studying the effect on tumor growth of both 
anemia, blood transfusion and iron therapy will play a pivotal role. These animal experiments should 
precede a clinical trial studying the long-term effects of iron therapy. If anemia is proven to be 
significantly associated with highest tumor growth, the clinical study design should be reconsidered. 
This could, for example, include the administration of iron therapy in all anemic patients, subdivided 
into patients with iron-dependent and non-iron dependent colorectal tumor phenotypes. Assessment of 
the iron-dependency of the tumor could be done by identification of gene and protein expression levels 
of iron transporters. If iron therapy is proven to be significantly associated with impaired tumor 
prognosis in the iron-dependent group, this probably indicates the hazardous effect of iron therapy. 
Interestingly, corroborating data about the possible detrimental effects of iron can be deduced from a 
report by Harlaar et al,
39
 comparing the long-term effects of autologous and allogeneic blood 
transfusions in colorectal cancer patients. They unexpectedly showed that patients with autologous 
blood transfusion, with an a priori lower probability to dysregulate the immune system of the recipient, 
showed an inferior long-term survival as compared to patients transfused with allogeneic blood. 
Interestingly, the patients with autologous blood transfusion additionally received preoperative oral iron 
therapy to maintain normal hemoglobin levels after blood donation. 
  
In conclusion, if iron therapy indeed can be shown to worsen colorectal tumor prognosis, this should 
change current management of anemia in colorectal cancer patients. Focus will be shifted, and 
minimization of the use of blood transfusions will no longer be the main objective. Paradigms will be 
shifted in patient blood management, which will bear major changes in oncological care as a whole.   
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